The new year brought many policy changes that can affect payments for drugs, not the least of which was the Centers for Medicare & Medicaid Services’ (CMS’s) new rule that, as of Jan. 1, 2018, each biologic, reference product and biosimilar must have its own unique billing code.
“This shift in policy is vital for patients, representing a big step forward toward supporting a robust and competitive biologics marketplace that increases access and reduces costs